ADIA Nutrition, Inc. Reports Strong Revenue Growth And Operational Momentum For First Quarter 2026

(MENAFN- Newsfile Corp) ADIA Nutrition, Inc. Reports Strong Revenue Growth and Operational Momentum for First Quarter 2026

May 15, 2026 7:59 AM EDT | Source: Adia Nutrition Inc.

Winter Park, Florida--(Newsfile Corp. - May 15, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a leader in advanced nutrition and regenerative health solutions, today announced its 3^rd party reviewed financial results for the first quarter ended March 31, 2026, highlighting significant year-over-year revenue growth and continued expansion of its biologics and medical procedures segments.

To view an enhanced version of this graphic, please visit:

Key Highlights for Q1 2026 (compared to Q1 2025):

Total Revenue increased 146% to $176,275 from $71,764, reflecting strong demand and successful diversification of revenue streams.
Medical Procedures Revenue grew 48% to $104,850 from $70,700, demonstrating continued patient adoption of ADIA's innovative regenerative therapies.
Biologics Sales delivered $69,775 in new revenue (compared to $0 in the prior-year period), marking the successful commercialization and rapid traction of the Company's high-margin biologic products.
Gross Profit surged 381% to $67,577 from $14,052, driven by a higher-margin revenue mix and improved operational efficiencies.
Cash Position strengthened to $136,716 at quarter-end (versus $37,463 at the end of Q1 2025), supported by disciplined financing activities.
Deferred Revenue rose sharply to $218,000 from $14,000, indicating robust forward sales momentum and committed future revenue.
Total Assets increased 31% to $776,868 from $594,826 at December 31, 2025, bolstered by higher inventory, receivables, and cash balances.

"ADIA Nutrition delivered exceptional top-line growth in the first quarter as we continue to scale our regenerative health platform," said Larry Powalisz CEO. "Revenue more than doubled year-over-year, with the addition of a new biologics' revenue stream and nearly 50% growth in medical procedures. Our gross profit nearly quadrupled, and we entered the second quarter with significantly higher cash and a strong deferred revenue backlog. These results validate our strategy and position us for accelerated growth in 2026." The Company expanded its biologics inventory to meet rising demand and continued strategic investments in equipment and infrastructure to support future expansion.

MENAFN15052026004218003983ID1111120921